Leading late-stage immunotherapy company harnessing immunogenic cell death by orchestrating both the innate (NK) and adaptive (T Cell) immune system through first-in-class immunological platforms.
ImmunityBio (formerly NantCell) develops novel combinations of chemo-immune sensitizers, cell therapies, cytokines, vaccines, neoepitopes, and monoclonal antibody immunotherapies to orchestrate the NK and T Cell response for cancer and infectious diseases.